Severity
Low
FDA Drug recall · Reported March 5, 2014
Subpotent Drug: Drug potency was compromised during shipment.
Actavis recalled Gelnique (oxybutynin chloride) Gel 10%, 100 mg in 1 g sachet, for topical use only. Phys… - a low-severity action.
Gelnique (oxybutynin chloride) Gel 10%, 100 mg in 1 g sachet, for topical use only. Phys… was recalled by Actavis in March 5, 2014. Reason: Subpotent Drug: Drug potency was compromised during shipment.. Check the official notice for the remedy. Verify recall #D-1088-2014 with the FDA Drug before acting.
The recall
Actavis issued this low-severity FDA Drug recall-Subpotent Drug: Drug potency was compromised during shipment..
Sourced from official FDA Drug enforcement records. Verify recall #D-1088-2014 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1088-2014) was formally reported on March 5, 2014, with the manufacturer initiating the action on February 7, 2014. It is classified under Low severity (Class III), with a current status of Terminated. Actavis is listed as the recalling firm, operating out of Salt Lake City, UT. Federal records list the affected scope as 38,227 Clamshells.
The documented reason for this recall is: Subpotent Drug: Drug potency was compromised during shipment. Distribution data in the federal record shows the product reached: Distributed nationwide to physicians as samples. No military/ govt/ VA or foreign consignees.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
38,227 Clamshells
Related Recalls
6
5 from same agency
Gelnique (oxybutynin chloride) Gel 10%, 100 mg in 1 g sachet, for topical use only. Physician sample in clamshell container with seven heat-sealed sachets. Rx Only. Watson Pharmaceuticals Inc, Corona, CA, 92890. NDC: 52544-084-77.
Subpotent Drug: Drug potency was compromised during shipment.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-1088-2014 |
| Date reported | March 5, 2014 |
| Date initiated | February 7, 2014 |
| Recalling firm | Actavis |
| Firm location | Salt Lake City, UT |
| Affected scope | 38,227 Clamshells |
| Distribution | Distributed nationwide to physicians as samples. No military/ govt/ VA or foreign consignees. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported March 5, 2014. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.